Mitochondrial Disruption by Amyloid Beta 42 Identified by Proteomics and Pathway Mapping

Area of Science:

• Neuroscience
• Biochemistry
• Cell Biology

Background:

• Alzheimer's disease (AD) is characterized by neurodegeneration and amyloid beta (Aβ) plaques.
• Increased Aβ fragments are observed in AD patients, making anti-amyloid therapies a focus.
• The neurotoxic effects of soluble Aβ, particularly Aβ42, are linked to cellular dysfunction.

Purpose of the Study:

• To investigate the impact of Aβ42 on the proteome of nerve growth factor-differentiated PC12 cells.
• To identify specific proteins and pathways affected by Aβ42 exposure.
• To understand the role of Aβ42 in mitochondrial network adaptations and neurotoxicity.

Main Methods:

• Utilized liquid-chromatography electrospray ionization mass spectrometry (LC-ESI MS/MS) proteomics.
• Employed whole-cell peptide mass fingerprinting.
• Integrated bioinformatic gene set enrichment analysis (GSEA) for pathway identification.

Main Results:

• Aβ42 significantly disrupted proteome responses related to cellular signaling.
• Evidence suggests Aβ42 impacts mitochondrial bioenergetics and morphology.
• Specific components of the mitochondrial response to Aβ42 neurotoxicity were identified.

Conclusions:

• Aβ42 plays a crucial role in disrupting mitochondrial function, contributing to neurotoxicity in Alzheimer's disease.
• The study highlights key mitochondrial pathways affected by Aβ42.
• Identified proteins and pathways may serve as novel biomarkers for amyloid disease detection and monitoring.